Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
暂无分享,去创建一个
R. Herbst | C. Ng | R. Kurzrock | R. Benjamin | M. Bass | L. Rosen | Yu‐Nien Sun | A. Polverino | J. Wiezorek | M. Mulay | A. V. Van Vugt | M. Purdom | J. Silverman | A. Koutsoukos | R. Xu | David D. Chang
[1] H. Dvorak. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[3] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[4] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Busse,et al. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. , 1999, Cardiovascular research.
[6] R. Herbst,et al. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors , 2005 .
[7] R. Gray,et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 , 2005 .
[8] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[9] R. Herbst,et al. 151 AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors , 2004 .
[10] P. Hoff,et al. Angiogenesis inhibitors in the treatment of cancer , 2005, Expert opinion on pharmacotherapy.
[11] H. Wakelee,et al. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. , 2005, Clinical lung cancer.
[12] R. Herbst,et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Palmer,et al. Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. , 2004, Blood.
[14] Ling Wang,et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. , 2006, Cancer research.
[15] J. Berlin,et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Jackson,et al. The effect of AMG 706, a novel multi-kinase inhibitor, on vascular permeability and blood flow as assessed by dynamic contrast enhanced magnetic resonance imaging in an in vivo preclinical tumor model , 2005 .
[17] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Kathleen M Sakamoto. Su-11248 Sugen. , 2004, Current opinion in investigational drugs.
[19] Tim Eisen,et al. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[20] Eric Masson,et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Chang-Ho Ahn,et al. Regulatory considerations for preclinical development of anticancer drugs , 1997, Cancer Chemotherapy and Pharmacology.
[22] A. Luttun,et al. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? , 2003, The Journal of clinical investigation.
[23] C. Moskaluk,et al. Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.